



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 400  
Washington, DC 20503-0400  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10 060,255	02 01 2002	Craig A. Rosen	PZ042P1C1	9759

22195 7590 09 04 2003

HUMAN GENOME SCIENCES INC  
9410 KEY WEST AVENUE  
ROCKVILLE, MD 20850

EXAMINER

STEADMAN, DAVID J

ART UNIT PAPER NUMBER

1652

DATE MAILED: 09/04/2003

7

Please find below and/or attached an Office communication concerning this application or proceeding.

Application No.

Applicant(s)

10/060,255

ROSEN ET AL.

**Office Action Summary**

Examiner

Art Unit

David J Steadman

1652

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-24 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-24 are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- \* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_.
- 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_

Art Unit: 1652

## **DETAILED ACTION**

### ***Status of the Application***

- [1] Claims 1-24 are pending in the application.
- [2] Applicant's amendment to the specification, amendment to claims 17 and 21, and addition of claim 24 in Paper No. 7, filed February 01, 2002, is acknowledged.

### ***Election/Restrictions***

- [3] Restriction to *one* of the following inventions is required under 35 U.S.C. 121:
- I. Claims 1-10, 14, 15, and 21, drawn to an isolated nucleic acid, a recombinant vector, a method of making recombinant host cell, a recombinant host cell, a method of making an isolated polypeptide, and a gene, classified in class 435, subclass 69.1.
  - II. Claims 11-12 and 16, drawn to an isolated polypeptide, classified in class 530, subclass 350.
  - III. Claims 13, drawn to an isolated antibody, classified in class 530, subclass 387.9.
  - IV. Claim 23, drawn to a polypeptide binding partner, classified in class 530, subclass 350.
  - V. Claim 17, drawn to a method for preventing, treating, or ameliorating a medical condition by administering a polypeptide, classified in class 514, subclass 2.
  - VI. Claim 18, drawn to a method of diagnosing a pathological condition by determining the presence or absence of a mutation in a polynucleotide, classified in class 435, subclass 6.
  - VII. Claim 19, drawn to a method of diagnosing a pathological condition by determining the presence or amount of expression of a polypeptide, classified in class 435, subclass 7.1.
  - VIII. Claim 20, drawn to a method for identifying a polypeptide binding partner, classified in class 435, subclass 7.1.
  - IX. Claim 22, drawn to a method for identifying an activity in a biological assay, classified in class 435, subclass 7.1.

Art Unit: 1652

- X. Claim 24, drawn a method for preventing, treating, or ameliorating a medical condition by administering a polypeptide, classified in class 514, subclass 44.

[4] If applicant should elect the invention of Group I, VI, or X, restriction to *one* of the following is also required under 35 USC 121.

- a) A polynucleotide encoding SEQ ID NO:42 including SEQ ID NO:11.
- b) A polynucleotide encoding SEQ ID NO:43 including SEQ ID NO:12.
- c) A polynucleotide encoding SEQ ID NO:44 including SEQ ID NO:13.
- d) A polynucleotide encoding SEQ ID NO:45 including SEQ ID NO:14.
- e) A polynucleotide encoding SEQ ID NO:46 including SEQ ID NO:15.
- f) A polynucleotide encoding SEQ ID NO:47 including SEQ ID NO:16.
- g) A polynucleotide encoding SEQ ID NO:48 including SEQ ID NO:17.
- h) A polynucleotide encoding SEQ ID NO:49 including SEQ ID NO:18.
- i) A polynucleotide encoding SEQ ID NO:50 including SEQ ID NO:19.
- j) A polynucleotide encoding SEQ ID NO:51 including SEQ ID NO:20.
- k) A polynucleotide encoding SEQ ID NO:52 including SEQ ID NO:21.
- l) A polynucleotide encoding SEQ ID NO:53 including SEQ ID NO:22.
- m) A polynucleotide encoding SEQ ID NO:54 including SEQ ID NO:23.
- n) A polynucleotide encoding SEQ ID NO:55 including SEQ ID NO:24.
- o) A polynucleotide encoding SEQ ID NO:56 including SEQ ID NO:25.
- p) A polynucleotide encoding SEQ ID NO:57 including SEQ ID NO:26.
- q) A polynucleotide encoding SEQ ID NO:58 including SEQ ID NO:27.
- r) A polynucleotide encoding SEQ ID NO:59 including SEQ ID NO:28.
- s) A polynucleotide encoding SEQ ID NO:60 including SEQ ID NO:29.
- t) A polynucleotide encoding SEQ ID NO:61 including SEQ ID NO:30.
- u) A polynucleotide encoding SEQ ID NO:62 including SEQ ID NO:31.
- v) A polynucleotide encoding SEQ ID NO:63 including SEQ ID NO:32.
- w) A polynucleotide encoding SEQ ID NO:64 including SEQ ID NO:33.
- x) A polynucleotide encoding SEQ ID NO:65 including SEQ ID NO:34.
- y) A polynucleotide encoding SEQ ID NO:66 including SEQ ID NO:35.
- z) A polynucleotide encoding SEQ ID NO:67 including SEQ ID NO:36.
- aa) A polynucleotide encoding SEQ ID NO:68 including SEQ ID NO:37.

Art Unit: 1652

- bb) A polynucleotide encoding SEQ ID NO:69 including SEQ ID NO:38.
- cc) A polynucleotide encoding SEQ ID NO:70 including SEQ ID NO:39.
- dd) A polynucleotide encoding SEQ ID NO:71 including SEQ ID NO:40.
- ee) A polynucleotide encoding SEQ ID NO:72 including SEQ ID NO:41.

**[5]** If applicant should elect the invention of Group II, III, IV, V, VII, VIII, or IX, restriction to *one* of the following is also required under 35 USC 121.

- |                                      |                                       |
|--------------------------------------|---------------------------------------|
| ff) The polypeptide of SEQ ID NO:42. | vv) The polypeptide of SEQ ID NO:58.  |
| gg) The polypeptide of SEQ ID NO:43. | ww) The polypeptide of SEQ ID NO:59.  |
| hh) The polypeptide of SEQ ID NO:44. | xx) The polypeptide of SEQ ID NO:60.  |
| ii) The polypeptide of SEQ ID NO:45. | yy) The polypeptide of SEQ ID NO:61.  |
| jj) The polypeptide of SEQ ID NO:46. | zz) The polypeptide of SEQ ID NO:62.  |
| kk) The polypeptide of SEQ ID NO:47. | aaa) The polypeptide of SEQ ID NO:63. |
| ll) The polypeptide of SEQ ID NO:48. | bbb) The polypeptide of SEQ ID NO:64. |
| mm) The polypeptide of SEQ ID NO:49. | ccc) The polypeptide of SEQ ID NO:65. |
| nn) The polypeptide of SEQ ID NO:50. | ddd) The polypeptide of SEQ ID NO:66. |
| oo) The polypeptide of SEQ ID NO:51. | eee) The polypeptide of SEQ ID NO:67. |
| pp) The polypeptide of SEQ ID NO:52. | fff) The polypeptide of SEQ ID NO:68. |
| qq) The polypeptide of SEQ ID NO:53. | ggg) The polypeptide of SEQ ID NO:69. |
| rr) The polypeptide of SEQ ID NO:54. | hhh) The polypeptide of SEQ ID NO:70. |
| ss) The polypeptide of SEQ ID NO:55. | iii) The polypeptide of SEQ ID NO:71. |
| tt) The polypeptide of SEQ ID NO:56. | jjj) The polypeptide of SEQ ID NO:72. |
| uu) The polypeptide of SEQ ID NO:57. |                                       |

**[6]** The inventions are distinct, each from the other because:

**[7]** The polynucleotides of Groups a)-ee) are structurally distinct, encode structurally distinct polypeptides, and no single polynucleotide of Groups a)-ee) would render any of the others obvious to one of ordinary skill in the art.

**[8]** The polypeptides of Groups ff)-jjj) are structurally distinct, elicit different antibodies, and no single polypeptide of Groups ff)-jjj) would render any of the others obvious to one of ordinary skill in the art.

Art Unit: 1652

**[9]** The polynucleotide of Group I, the polypeptide of Group II, the antibody of Group III, and the binding partner of Group IV each comprises a chemically unrelated structure capable of separate manufacture, use and effect. The polynucleotide of Group I has other utility besides encoding polypeptides such as being used as a hybridization probe and the polypeptide of Group II can be made by another method such as purification from the natural source or chemical synthesis.

**[10]** The polynucleotide of Group I is unrelated to the method(s) of Groups V and VII-IX as it is neither used nor made by the method(s) of Groups V and VII-IX.

**[11]** The polynucleotide of Group I and the methods of Groups VI and X are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polynucleotide of Group I can be used for protein expression.

**[12]** The polypeptide of Group II is unrelated to the method(s) of Group VI and X as it is neither used nor made by the method(s) of Group VI.

**[13]** The polypeptide of Group II and the methods of Groups V and VII-IX are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the polypeptide of Group II can be used as an antigen in the production of antibodies.

**[14]** The antibody of Group III is unrelated to the method(s) of Groups V-X as it is neither used nor made by the method(s) of Groups V-IX.

**[15]** The polypeptide binding partner of Group IV is unrelated to the method(s) of Groups V-X as it is neither used nor made by the method(s) of Groups V-IX.

Art Unit: 1652

**[16]** The methods of Groups V-X are independent as they comprise different steps, utilize different products and yield different results.

**[17]** MPEP § 803 sets forth two criteria for a proper restriction between patentably distinct inventions: (A) The inventions must be independent or distinct as claimed and (B) There must be a serious burden on the examiner. As shown above, each of the inventions of Groups a)-jjj) and I-X are independent or distinct, thus satisfying the first criterion for a proper restriction. MPEP § 803 additionally states that a serious burden on the examiner may be prima facie shown if the examiner shows by appropriate explanation either separate classification, separate status in the art, or a different field of search. Each of the inventions requires a separate patent and non-patent literature search requiring a different text and/or sequence search for each Group and thus, co-examination of the inventions of Groups a)-jjj) and I-X would be a serious burden on the examiner.

**[18]** It is noted that claims 1-24 will be examined only to the extent the claims read on the elected subject matter.

**[19]** Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

**[20]** Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David Steadman, whose telephone number is (703) 308-3934. The Examiner can normally be reached Monday-Friday from 7:00 am to 5:00 pm. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (703) 308-3804. The FAX number for submission of official papers to Group 1600 is (703) 308-4242. Draft or informal FAX communications should be directed to (703) 746-5078. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Art Unit receptionist whose telephone number is (703) 308-0196.

David J. Steadman  
Patent Examiner

*[Signature]*  
05/30/03